This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The inspection was conducted from July 22-25, 2025
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
